Association Between Pre-operative Use of Non-selective Beta-blockers With the Risk of Hepatocellular Carcinoma Recurrence Following Liver Transplantation : a Retrospective Cohort Study
Overview
- Phase
- Not Applicable
- Intervention
- Non-Selective Beta-Adrenoreceptor Agonists for Systemic Use
- Conditions
- Hepatocellular Carcinoma Recurrent
- Sponsor
- Asan Medical Center
- Enrollment
- 2092
- Primary Endpoint
- Kaplan-Meier survival analysis of HCC recurrence at 5-year follow-up
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
The goal of this observational study is to investigate the effect of non-selective beta-blocker (NSBB) on the recurrence of hepatocellular carcinoma (HCC) following liver transplantation in patients who underwent liver transplantation (LT) for treating hepatocellular carcinoma.
The main question[s] it aims to answer are:
- Is the usage of non-selective beta-blocker associated with decreased recurrence of hepatocellular carcinoma following liver transplantation?
- Is the usage of non-selective beta-blocker associated with all-cause mortality following liver transplantation?
Researchers will compare the NSBB group, including patients who received non-selective beta-blocker therapy for at least 30 consecutive days within 3 months prior to liver transplantation more than 30 days prior, with the control group to to see if non-selective beta-blocker treatment is associated with decreased recurrence of hepatocellular carcinoma following liver transplantation.
Investigators
Jun-Gol Song
Professor
Asan Medical Center
Eligibility Criteria
Inclusion Criteria
- •Adult patients
- •Underwent liver transplantation for treating hepatocellular carcinoma
- •Between Jan. 2008 - May. 2022
Exclusion Criteria
- •Pediatric patients (Age under 18 years)
- •Re-transplantation
- •Multi-organ transplantation
Arms & Interventions
NSBB group
The NSBB group was defined as those who received NSBBs for at least 30 consecutive days within the 3 months prior to LT.
Intervention: Non-Selective Beta-Adrenoreceptor Agonists for Systemic Use
Outcomes
Primary Outcomes
Kaplan-Meier survival analysis of HCC recurrence at 5-year follow-up
Time Frame: Baseline and 5-year follow-up
HCC recurrence, which was diagnosed based on pathological or radiographic evidence of new lesions consistent with HCC, and recurrence-free survival was collected and compared using Kaplan-Meier survival analysis.
Multivariate Cox regression analysis of HCC recurrence at 5-year follow-up
Time Frame: Baseline and 5-year follow-up
Multivariate Cox regression analysis was performed to identify the risk factors for HCC recurrence.
Secondary Outcomes
- Kaplan-Meier survival analysis of overall survival at 5-year follow-up(Baseline and 5-year follow-up)
- Multivariate Cox regression analysis of overall survival at 5-year follow-up(Baseline and 5-year follow-up)